While we are unquestionably living in a golden age for biopharma drug discovery and development, 2023 is also proving a tough time to be an early-stage biotech company.
That is because the ‘easy money’ days of 2021 have evaporated, and many start-ups launched in the boom times now face a relative funding drought as they look to reach...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?